AstraZeneca, Cellectis join forces to boost cell, gene therapy innovations
AstraZeneca announced a strategic collaboration and investment agreement with Cellectis, a leader in clinical-stage biotechnology. This partnership, valued initially at $105 million, signifies a substantial ... Read More
Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma
Cellectis said that it has dosed the first patient in a phase 1 study - the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf ... Read More